Trial Profile
Effect of Sofosbuvir or Ledipasvir/Sofosbuvir Therapy on Liver Fibrosis in Japanese Patients with Hepatitis C Virus Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatic fibrosis; Hepatitis C
- Focus Therapeutic Use
- 26 Mar 2021 Primary endpoint (change of M2BPGi at 24 weeks after SVR achievement (changes from baseline to 48 weeks in M2BPGi)) has been met.
- 26 Mar 2021 Results published in the Medicine.
- 26 Mar 2021 Status changed from active, no longer recruiting to completed.